Losartan Use in Chickens: Safety, Dosage, and Practical Cautions

There is no established, evidence‑based dosage or safety guidance for using losartan (an angiotensin II receptor blocker, ARB) in chickens. Available avian research suggests that the typical losartan target (AT1 receptor) may not function in domestic fowl the same way it does in mammals, meaning the drug may not produce the expected effects and could be unreliable or inappropriate for poultry care. ^[1] In the absence of veterinary formulary dosing, and given species differences in receptor biology, routine administration of losartan to chickens is not recommended unless under a veterinarian’s direct supervision for a specific research or clinical rationale. ^{[2] [3]}

---

What the Science Shows in Birds

• Different angiotensin receptors in fowl: In anesthetized domestic fowl, experimental doses of losartan (10 mg/kg IV; cumulative 1–20 mg/kg) did not selectively block angiotensin II effects on blood pressure or vascular tone, and did not inhibit angiotensin II–induced vasorelaxation in aortic ring assays. This indicates losartan’s usual target (AT1) blockade does not translate to predictable vascular effects in chickens. ^[1]

• Implication: Because the drug’s mechanism appears mismatched to avian receptor subtypes, therapeutic efficacy is uncertain in chickens, even at high experimental doses. ^[1]

---

Lack of Veterinary Dosing Guidance

• No poultry dosing standards: Standard veterinary formularies and poultry practice guidelines do not provide dosing recommendations for losartan in chickens. There is no validated mg/kg dosing, route, or duration for clinical use in poultry. ^{[2] [3]}

• Extrapolation risks: Avian pharmacokinetics differ from mammals (metabolism, distribution, GI and respiratory physiology), so simple dose scaling from human or dog/cat regimens is not reliable and can be unsafe. ^{[2] [3]}

---

Safety Considerations and Potential Risks

• Uncertain benefit with potential harm: Since losartan’s intended receptor blockade does not behave as expected in fowl, using it may expose birds to unnecessary drug without clear benefit. ^[1]

• Class warnings (mammalian data): In mammals, ARBs like losartan can affect developing fetuses and neonates, with reports of decreased weight and renal toxicity in rodent studies during late gestation through lactation. While these data are not in chickens, they raise caution for use in breeding birds, layers, or chicks. ^{[4] [5]}

• Off‑label use and residues: Any off‑label medication in food‑producing animals demands strict attention to withdrawal times and residue avoidance, which are not established for losartan in poultry. This makes use in meat or egg‑producing birds inappropriate. ^{[2] [3]}

---

Practical Guidance for Poultry Care

• Avoid routine losartan use: Given receptor differences and lack of dosing, do not use losartan for hypertension, heart, or kidney issues in chickens without a veterinarian’s explicit guidance. ^{[1] [2]}

• Seek avian‑specific alternatives: When cardiovascular or renal support is needed, avian veterinarians typically consider drugs with known avian pharmacokinetics and clinical experience, adjusting therapy based on species‑specific responses. ^{[2] [3]}

• Research settings only: If losartan is considered in a research protocol, close monitoring, serial blood sampling, and ethics compliance are essential; established techniques for ulnar vein cannulation can support pharmacokinetic sampling in chickens. ^[6]

---

Summary Table: Losartan in Chickens

Topic	Evidence/Status	Key Takeaway
Mechanism in fowl	Losartan did not selectively block angiotensin II effects in domestic fowl; receptor subtype behavior differs from mammals. [1]	Efficacy is uncertain; mechanism may not apply.
Veterinary dosing	No validated poultry dosing or routes published. [2] [3]	No recommended mg/kg; avoid extrapolation.
Safety	Mammalian data warn of fetal/neonatal risks; no avian safety data or withdrawal times. [4] [5]	Use is risky, especially in breeders/layers.
Clinical use	Not recommended for routine poultry care; consider avian‑specific treatments. [2] [3]	Consult an avian veterinarian.
Research use	Possible only with strict monitoring and serial sampling techniques. [6]	Research‑only with oversight.

---

Bottom Line

Based on current evidence, losartan is not considered safe or appropriate for routine use in chickens, largely because it does not reliably block angiotensin pathways in fowl and there is no established dosing guidance for poultry. ^{[1] [2] [3]} If a cardiovascular or renal issue is suspected in chickens, work with an avian veterinarian to select therapies with proven avian efficacy and safety, and avoid off‑label ARB use in food‑producing birds due to residue concerns and lack of withdrawal times. ^{[2] [3]}